Scrip
US FDA to reivew extended-release Aricept NDA
25 November 2009
Katie McQue
Please Login to read the full article.
25 November 2009
Katie McQue
The US FDA has accepted for review Pfizer and Eisai's NDA for a higher-dose 23mg once-daily extended-release formulation of their Alzheimer's drug Aricept (donepezil HCl extended release).
The NDA is based in a 1,400 patient head-to-head study comparing the 23mg formulation of Aricept to...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novo Nordisk's diabetes drug liraglutide stumbles on thyroid cancer concerns
- US panel backs Acorda's fampridine for MS, but urges study of lower dose
- US panel calls for phased launch of Neuromed/Covidien's long-acting opioid Exalgo
- Caduet's Japanese price may set precedent for combinations
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
